Chinese Peptide Company’s Post

Working in Oncology? Learn how the ClinoStar promotes uniform cell aggregation resulting in consistent tumoroid size and structure. #celvivo #cellculture #onclolgy #tumoroids #cancer https://lnkd.in/eRmHJP7e

Pleased to announce the publication of our correspondence in Annals of Oncology regarding our work on predictive transcriptomic signatures for pancreatic cancer treatments! 🔹 We address concerns about resistance to mFOLFIRINOX and gemcitabine, and are actively investigating dual-resistant patients to identify new therapeutic options. 🔹 Our model could enable less toxic treatments, like gemcitabine for those predicted to respond well, reducing side effects. 🔹 Importantly, the predictive signatures have proven effective across different patient groups and biopsy types, guiding treatment decisions for both operable and metastatic patients and reinforcing their potential for personalized treatment. CRCM - Centre de Recherche en Cancérologie de Marseille https://lnkd.in/e272xWey

Castration-Resistant Prostate Cancer (CRPC) Treatment Market size to grow by USD 5.98 billion from 2023 to 2028, North America to account for 47% of market growth- Technavio: NEW YORK, Jan. 8, 2024 /PRNewswire/ -- The castration-resistant prostate cancer (CRPC) treatment market is expected to grow by USD 5.98 billion from 2023 to 2028. In addition, the momentum of the market will progress at a CAGR of 8.83% during the forecast period, according to Technavio...

Brilliantly designed I-SPY2 trial - adaptive neoadjuvant treatments for early breast cancer, stratified by receptor status, DNA repair deficiency & immunogenicity and tailored according to predicted response. The ADC/IO synergy continues to grow & this trial could really set the platform for personalised de-escalation & intensification approaches. Great abstract at #ESMO24. https://lnkd.in/egvFU62r ESMO - European Society for Medical Oncology

[NEW PAPER] Combitherapy in Preclinical Breast Cancer HR+/HER2- Models 🤔 How using PDX Models for translational research demonstrate ways to overcome resistance? Based on the scientific paper "𝐃𝐨𝐮𝐛𝐥𝐞𝐭 𝐚𝐧𝐝 𝐓𝐫𝐢𝐩𝐥𝐞𝐭 𝐂𝐨𝐦𝐛𝐢𝐧𝐚𝐭𝐢𝐨𝐧𝐬 𝐨𝐟 𝐄𝐫𝐢𝐛𝐮𝐥𝐢𝐧, 𝐅𝐮𝐥𝐯𝐞𝐬𝐭𝐫𝐚𝐧𝐭, 𝐚𝐧𝐝 𝐏𝐚𝐥𝐛𝐨𝐜𝐢𝐜𝐥𝐢𝐛 𝐢𝐧 𝐏𝐫𝐞𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐁𝐫𝐞𝐚𝐬𝐭 𝐂𝐚𝐧𝐜𝐞𝐫 𝐌𝐨𝐝𝐞𝐥𝐬" published in January and co-written by Oncodesign Services and Eisai Co., Ltd. , discover in this article a brief summary of the key findings to take away! Read now 👉https://lnkd.in/eQaAxS4p

Scientists have uncovered an RNA damage response network that plays a critical role in the lethality of 5-FU, a widely used chemotherapy drug for colorectal cancer. The study reveals that this network involves the activation of the PKR-eIF2α pathway and upregulation of the RNA modification m6A. These findings provide a better understanding of how 5-FU works and could lead to the development of more effective combination therapies for colorectal cancer treatment. #5FU #colorectalcancer #RNAdamageresponse #PKR #eIF2α #m6A https://lnkd.in/eaX2kE_Y

Understanding the Difference: BPH vs. Prostate Cancer 🔄 BPH (Benign Prostatic Hyperplasia) is a common condition causing enlarged prostate, while prostate cancer involves abnormal cell growth. Early detection and awareness are key to effective management.

Are you cultivating tumoroids? Are you interested to learn about the rise of patient-derived organoids as game-changers in cancer research? Or are you interested to know about how to design in-vitro models for optimal cancer research? We have updated our oncology page with new white papers, blog posts, and videos to give you a complete overview of how to utilize 3D when working with cancer research. #Cancer #Tissue #3DCellCulture #Research #ClinoStar https://lnkd.in/dYakG4jK

The frequent overexpression of prostate-specific membrane antigen (PSMA) in prostate cancers opened the way for the development of tracers for diagnostic purposes and for therapeutic applications, thereby offering a more precise and personalised approach for the treatment of castration-resistant tumours. #cancer #oncology #PSMA #ProstateCa #enzalutamide

🎖Check out the Highly cited #Article "Approaches to the Management of Metastatic Adenoid Cystic Carcinoma" 👏by Rex Lee et al. University of California, San Francisco Find out more here▶️ https://lnkd.in/dZmpt9Wn Keywords: adenoid cystic carcinoma (ACC); salivary gland cancer; metastasis; systemic therapy; chemotherapy; tyrosine kinase inhibitor (TKI); immunotherapy; metastasectomy; radiation; SBRT